TAMPER-EVIDENT PACKAGING FOR DERMATOLOGICAL OTCs URGED BY ASHP
This article was originally published in The Tan Sheet
Executive Summary
TAMPER-EVIDENT PACKAGING FOR DERMATOLOGICAL OTCs URGED BY ASHP in March 18 comments on FDA's proposed rule on tamper-evident packaging requirements for OTCs published in the Jan. 18 Federal Register ("The Tan Sheet" Jan. 24, p. 1). While lending support to FDA's proposal to require that all two-piece, hard-shell caps sold over-the-counter be sealed, the American Society of Hospital Pharmacists recommended that FDA "reconsider its regulatory exclusion of other dosage forms from tamper-evident packaging requirements, including dermatologicals."